Consortium

 

The SAFE-T consortium is a unique public-private partnership that brings together pharmaceutical companies, universities, hospitals and biotechnology SMEs to share and validate each other's safety testing methods under advisement of the European Medicines Agency (EMA) and its US counterpart, the Food and Drug Administration (FDA). To generate enough clinical evidence for qualifying new safety biomarkers for pre-clinical and clinical regulatory decision-making needs full stakeholder cooperation of the following 25 consortium members:The SAFE-T consortium is a unique public-private partnership that brings together pharmaceutical companies, universities, hospitals and biotechnology SMEs to share and validate each other's safety testing methods under advisement of the European Medicines Agency (EMA).

 

EFPIA Members

Almirall (Almirall)
Amgen (Amgen)
AstraZeneca (AZ)
Bayer Healthcare Pharmaceuticals (BP)
Boerhinger Ingelheim (BI)
GlaxoSmithKline (GSK)
Eli Lilly (ELI)
Novartis (Novartis)
Pfizer (Pfizer)
Roche (Roche)
Sanofi-Aventis (Sanofi)

Academia

Assistance Publique Hôpitaux de Paris (APHP)
Charité Hospital (Charité)
Barcelona Cardiovascular Research Center (ICCC)
Natural and Medical Sciences Institute (NMI)
Tel Aviv (Sourasky) Medical Center (TASMC)
Universitätsklinikum Aachen (UKA)
Universität Leipzig (ULEI)
University of Liverpool (ULIV)
University of Malaga (UMA)
University College Dublin (UCD)

SMEs

Argutus Medical Limited (Argutus)
Experimental & Diagnostic Immunology GmbH (EDI)
Firalis SAS (Firalis)
Interface Europe (IE)

Advisors

European Medicines Agency (EMA)
Food and Drug Administration (FDA)

Collaborator

Critical Path Institute